Search

Displaying results 1251 - 1260 of 3732 in total
  1. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Methylprednisolone

    go.drugbank.com/drugs/DB00959
    ApprovedInvestigationalVet approved

    Methylprednisolone is a prednisolone derivative glucocorticoid with higher potency than prednisone. It was first described in the literature in the late 1950s. Methylprednisolone was granted FDA approval on 24 October 1957. In the outbre...

    Mixtures: P-Care D80, P-Care D40Categories: Corticosteroid Hormone Receptor Agonists, P-glycoprotein inducers
  3. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety,

  4. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists
  5. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

  6. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    [L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

  7. Target

    Transient receptor potential cation channel subfamily V member 1

    go.drugbank.com/bio_entities/BE0001023
    TargetHumans

    Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. … Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL.

    Polypeptides: Transient receptor potential cation channel subfamily V member 1Synonyms: Capsaicin receptor, Vanilloid receptor 1
  8. Target

    Low affinity immunoglobulin gamma Fc region receptor II-a

    go.drugbank.com/bio_entities/BE0002098
    TargetHumans

    Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-a
  9. Target

    Transient receptor potential cation channel subfamily V member 2

    go.drugbank.com/bio_entities/BE0009158
    TargetHumans

    Calcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...

    Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1
  10. Target

    Ankyrin repeat and protein kinase domain-containing protein 1

    go.drugbank.com/bio_entities/BE0009411
    TargetHumans

    Polypeptides: Ankyrin repeat and protein kinase domain-containing protein 1